Literature DB >> 15358643

Effect of photopheresis on lymphocyte population in children with newly diagnosed type 1 diabetes.

J Ernerudh1, J Ludvigsson, G Berlin, U Samuelsson.   

Abstract

In recent years photopheresis has been claimed to be an effective form of immunomodulation. It has also been shown to have an effect on the disease process at the onset of type 1 diabetes. In a double-blind, placebo-controlled randomized study, we analyzed if the effect of photopheresis in children with newly diagnosed diabetes is related to changes in the balance of lymhocyte populations. We also analyzed if lymphocyte subsets were related to recent infection, mild or aggressive disease manifestations, heredity, or gender. Nineteen children received active treatment with photopheresis, while 21 children received sham pheresis (placebo group). No influence of a history of previous infection, heredity, or certain clinical parameters on lymphocyte subsets was found. At the onset of type 1 diabetes, girls showed a higher proportion and a larger number of T cells (CD3+) and T-helper cells (CD4+) and a higher proportion of naïve CD4+ CD45RA+ cells. In the placebo group, an increase in the number of subsets with the activated phenotype in both the CD4(CD29+) and the CD8 (CD11a+) compartments was noted during the course of the study. These changes did not occur in the photopheresis group. No relation between lymphocyte subsets and clinical outcome was found 1 year after the treatment with photopheresis. In conclusion, we found no major effect of photopheresis on lymphocyte populations in a group of children with newly diagnosed type 1 diabetes. However, in the placebo group the proportions of activated CD4 and CD8 cells increased over time. Since these changes did not occur in the actively treated group, our findings suggest that photopheresis may have some suppressive effects.

Entities:  

Mesh:

Year:  2004        PMID: 15358643      PMCID: PMC515261          DOI: 10.1128/CDLI.11.5.856-861.2004

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  36 in total

1.  Antibody response to islet antigens in anti-CD4/prednisolone immune intervention of type 1 diabetes.

Authors:  K D Kohnert; B Hehmke; H Keilacker; M Ziegler; F Emmrich; F Laube; D Michaelis
Journal:  Int J Clin Lab Res       Date:  1996

Review 2.  Neuroendocrine and immune system interactions in stress and depression.

Authors:  A H Miller
Journal:  Psychiatr Clin North Am       Date:  1998-06

3.  CD4 and CD8 lymphocyte subsets in cerebrospinal fluid and peripheral blood from patients with multiple sclerosis, meningitis and normal controls.

Authors:  M Vrethem; C Dahle; C Ekerfelt; P Forsberg; O Danielsson; J Ernerudh
Journal:  Acta Neurol Scand       Date:  1998-04       Impact factor: 3.209

Review 4.  The pathogenesis of insulin-dependent diabetes mellitus.

Authors:  M A Atkinson; N K Maclaren
Journal:  N Engl J Med       Date:  1994-11-24       Impact factor: 91.245

5.  Treatment of psoriatic arthritis with extracorporeal photochemotherapy and conventional psoralen-ultraviolet A irradiation.

Authors:  C Vahlquist; M Larsson; J Ernerudh; G Berlin; T Skogh; A Vahlquist
Journal:  Arthritis Rheum       Date:  1996-09

6.  Increased CD69 and human leukocyte antigen-DR expression on T lymphocytes in insulin-dependent diabetes mellitus of long standing.

Authors:  A Gessl; W Waldhäusl
Journal:  J Clin Endocrinol Metab       Date:  1998-06       Impact factor: 5.958

7.  Lymphocyte subsets and mitogen stimulation of blood lymphocytes in normal pregnancy.

Authors:  L Matthiesen; G Berg; J Ernerudh; L Håkansson
Journal:  Am J Reprod Immunol       Date:  1996-02       Impact factor: 3.886

8.  A possible mechanism of psoralen phototoxicity not involving direct interaction with DNA.

Authors:  J D Laskin; E Lee; E J Yurkow; D L Laskin; M A Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1985-09       Impact factor: 11.205

9.  Aberrant activation of CD8+ T-cell and CD8+ T-cell subsets in patients with newly diagnosed IDDM.

Authors:  B Hehmke; D Michaelis; E Gens; F Laube; K D Kohnert
Journal:  Diabetes       Date:  1995-12       Impact factor: 9.461

10.  Low dose linomide in Type I juvenile diabetes of recent onset: a randomised placebo-controlled double blind trial.

Authors:  R Coutant; P Landais; M Rosilio; C Johnsen; N Lahlou; P Chatelain; J C Carel; J Ludvigsson; C Boitard; P F Bougnères
Journal:  Diabetologia       Date:  1998-09       Impact factor: 10.122

View more
  5 in total

1.  Guidelines on the use of extracorporeal photopheresis.

Authors:  R Knobler; G Berlin; P Calzavara-Pinton; H Greinix; P Jaksch; L Laroche; J Ludvigsson; P Quaglino; W Reinisch; J Scarisbrick; T Schwarz; P Wolf; P Arenberger; C Assaf; M Bagot; M Barr; A Bohbot; L Bruckner-Tuderman; B Dreno; A Enk; L French; R Gniadecki; H Gollnick; M Hertl; C Jantschitsch; A Jung; U Just; C-D Klemke; U Lippert; T Luger; E Papadavid; H Pehamberger; A Ranki; R Stadler; W Sterry; I H Wolf; M Worm; J Zic; C C Zouboulis; U Hillen
Journal:  J Eur Acad Dermatol Venereol       Date:  2014-01       Impact factor: 6.166

Review 2.  Extracorporeal photopheresis as a therapy for autoimmune diseases.

Authors:  Zoya Kuzmina; David Stroncek; Steven Z Pavletic
Journal:  J Clin Apher       Date:  2014-12-26       Impact factor: 2.821

3.  Regulatory T cell-associated activity in photopheresis-induced immune tolerance in recent onset type 1 diabetes children.

Authors:  C-O Jonson; M Pihl; C Nyholm; C M Cilio; J Ludvigsson; M Faresjö
Journal:  Clin Exp Immunol       Date:  2008-06-28       Impact factor: 4.330

Review 4.  Therapies to Preserve β-Cell Function in Type 1 Diabetes.

Authors:  Johnny Ludvigsson
Journal:  Drugs       Date:  2016-02       Impact factor: 11.431

5.  European dermatology forum - updated guidelines on the use of extracorporeal photopheresis 2020 - part 1.

Authors:  R Knobler; P Arenberger; A Arun; C Assaf; M Bagot; G Berlin; A Bohbot; P Calzavara-Pinton; F Child; A Cho; L E French; A R Gennery; R Gniadecki; H P M Gollnick; E Guenova; P Jaksch; C Jantschitsch; C Klemke; J Ludvigsson; E Papadavid; J Scarisbrick; T Schwarz; R Stadler; P Wolf; J Zic; C Zouboulis; A Zuckermann; H Greinix
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-10-06       Impact factor: 6.166

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.